Theriva Total Debt To Capitalization from 2010 to 2025

TOVX Stock  USD 1.20  0.03  2.56%   
Theriva Biologics Total Debt To Capitalization yearly trend continues to be fairly stable with very little volatility. Total Debt To Capitalization is likely to outpace its year average in 2025. During the period from 2010 to 2025, Theriva Biologics Total Debt To Capitalization regression line of annual values had r-squared of  0.02 and arithmetic mean of  0.05. View All Fundamentals
 
Total Debt To Capitalization  
First Reported
2010-12-31
Previous Quarter
0.07171373
Current Value
0.0753
Quarterly Volatility
0.01778097
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Theriva Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theriva Biologics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 101.5 K, Total Revenue of 0.0 or Other Operating Expenses of 14.4 M, as well as many indicators such as Price To Sales Ratio of 241, Dividend Yield of 0.0 or PTB Ratio of 0.12. Theriva financial statements analysis is a perfect complement when working with Theriva Biologics Valuation or Volatility modules.
  
Check out the analysis of Theriva Biologics Correlation against competitors.
For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.

Latest Theriva Biologics' Total Debt To Capitalization Growth Pattern

Below is the plot of the Total Debt To Capitalization of Theriva Biologics over the last few years. It is Theriva Biologics' Total Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Theriva Biologics' overall financial position and show how it may be relating to other accounts over time.
Total Debt To Capitalization10 Years Trend
Pretty Stable
   Total Debt To Capitalization   
       Timeline  

Theriva Total Debt To Capitalization Regression Statistics

Arithmetic Mean0.05
Geometric Mean0.05
Coefficient Of Variation33.97
Mean Deviation0.01
Median0.05
Standard Deviation0.02
Sample Variance0.0003
Range0.0772
R-Value(0.13)
Mean Square Error0.0003
R-Squared0.02
Significance0.64
Slope(0.0005)
Total Sum of Squares0

Theriva Total Debt To Capitalization History

2025 0.0753
2024 0.0717
2023 0.0515
2022 0.0299
2021 0.0228
2020 0.0556

About Theriva Biologics Financial Statements

Theriva Biologics investors use historical fundamental indicators, such as Theriva Biologics' Total Debt To Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Theriva Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Debt To Capitalization 0.07  0.08 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Theriva Stock Analysis

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.